<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28781" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Scleroderma (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Odonwodo</surname>
            <given-names>Amaka</given-names>
          </name>
          <aff>University Of Cincinnati</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Badri</surname>
            <given-names>Talel</given-names>
          </name>
          <aff>University of Tunis El Manar</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hariz</surname>
            <given-names>Anis</given-names>
          </name>
          <aff>Charles Nicolle Hospital, Un. of Tunis El Manar</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amaka Odonwodo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Talel Badri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anis Hariz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28781.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Scleroderma is a connective tissue disorder characterized primarily by the thickening and hardening of the skin. The combining form &#x0201c;sclero&#x0201d; means "hard" in Greek, and the word &#x0201c;dermis&#x0201d; means skin.&#x000a0;There are two primary types of scleroderma: localized and systemic (also called systemic sclerosis). In localized scleroderma, the disease affects mainly the skin and may have an impact on the muscles and bones. In systemic scleroderma, there is an involvement of the internal organs, such as the digestive tract, heart, lungs, and kidneys, among others. The severity and outcome of scleroderma are variable.<xref ref-type="bibr" rid="article-28781.r1">[1]</xref><xref ref-type="bibr" rid="article-28781.r2">[2]</xref></p>
      </sec>
      <sec id="article-28781.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>The causes of scleroderma are not fully known. There is some&#x000a0;evidence that genetic and environmental factors play a role in the genesis of scleroderma. Silica and certain organic solvents are recognized as risk factors of occurrence of systemic scleroderma. The result is an activation of the immune system, causing blood vessel&#x000a0;damage and injury to tissues that result in scar tissue formation and the accumulation of excess collagen.</p>
        <p>Genetic factors play at least a limited role.&#x000a0;According to&#x000a0;three US cohorts, the prevalence of the disease was 13 times higher in first-degree relatives of scleroderma patients than in&#x000a0;the general&#x000a0;population. OX40L gene polymorphism correlates with systemic scleroderma. IRF5 gene was found to correlate with systemic scleroderma as well as with the occurrence of interstitial lung disease during scleroderma.<xref ref-type="bibr" rid="article-28781.r3">[3]</xref><xref ref-type="bibr" rid="article-28781.r4">[4]</xref><xref ref-type="bibr" rid="article-28781.r5">[5]</xref><xref ref-type="bibr" rid="article-28781.r6">[6]</xref></p>
      </sec>
      <sec id="article-28781.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Scleroderma is a rare disease. Its prevalence varies with ethnicity, gender, and geographic area. In France, the estimated incidence of systemic sclerosis was 158.3 per million in 2002, mostly limited to the cutaneous forms. The prevalence of the disease in Detroit was 242 cases per million adults with an annual incidence of 19.3 new cases per year per million adults over the period 1989-91. As in numerous other autoimmune diseases, women are at higher risk than men (ratio 4.6:1). Systemic scleroderma can occur at any age; however, it is rare in children and the elderly. The disease is most prevalent in individuals aged 30-50 years.</p>
        <p>Localized scleroderma affects mostly women with an incidence of 3 cases per 100,000 individuals/year. Plaque form (also called morphea) is more prevalent in adults while linear scleroderma affects mostly children.<xref ref-type="bibr" rid="article-28781.r1">[1]</xref><xref ref-type="bibr" rid="article-28781.r7">[7]</xref><xref ref-type="bibr" rid="article-28781.r8">[8]</xref></p>
      </sec>
      <sec id="article-28781.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Three primary mechanisms contribute to the development of the scleroderma: vascular anomalies, excess fibrosis, and autoimmune phenomenon.</p>
        <p>Abnormal interactions between endothelial cells, fibroblasts, and lymphocytes (B and T) lead to microcirculatory vascular involvement. The endothelial cells produce large amounts of endothelin 1, causing vasoconstriction and fibroblast activation. Also, fibroblasts and activated endothelial cells produce reactive oxygen species that speed up vascular remodeling, leading to the obliteration of small vessels. Activated fibroblasts differentiate easily into myofibroblasts, which have increased collagen synthesis ability.<xref ref-type="bibr" rid="article-28781.r6">[6]</xref><xref ref-type="bibr" rid="article-28781.r9">[9]</xref></p>
      </sec>
      <sec id="article-28781.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>There are two primary forms of scleroderma: localized scleroderma and systemic scleroderma also called systemic sclerosis (SSc). &#x000a0;</p>
        <p>
<bold>Localized scleroderma</bold>
</p>
        <p>Localized scleroderma is limited to the skin and underlying tissue. It generally&#x000a0;evolves in three consecutive phases: edematous, indurated and sclerotic, and then atrophic. Its outcome is unpredictable and spontaneous improvements are possible. Different clinical forms of localized scleroderma can coexist in the same patient. There are two main groups of localized scleroderma: morphea and linear scleroderma.<xref ref-type="bibr" rid="article-28781.r1">[1]</xref><xref ref-type="bibr" rid="article-28781.r10">[10]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Morphea is the most common clinical form. It presents as a single or multiple plaques. These plaques are initially erythematous and then become sclerous, white, indurated, surrounded by a characteristic erythematous halo called &#x0201c;purple ring&#x0201d; reflecting its inflammatory activity. It is generally&#x000a0;painless, but pruritus may be present. Later, hypopigmentation appears, and the lesions become generally&#x000a0;atrophic. The lesions&#x000a0;are mainly on the trunk and proximal extremities; the face is rarely affected.&#x000a0;</p>
          </list-item>
        </list>
        <p>Plaque morphea can further classify into other sub-types, according to the shape or depth of the lesions. &#x0201c;Guttate&#x0201d; morphea or &#x0201c;white spot disease&#x0201d; refers to &#x0201c;drop-like&#x0201d;&#x000a0; shaped areas of skin involvement, whereas &#x0201c;subcutaneous&#x0201d; or deep morphea indicates a substantial involvement of deeper tissues with relative sparing of the overlying skin. The subcutaneous type may rarely extend deep into muscle tissues, but this does not indicate internal organ involvement.</p>
        <p>Generalized morphea is defined as multiple morphea plaques, confluent or not, affecting more than two anatomical sites.</p>
        <p>Bullous morphea is a rare sub-type characterized by blisters or erosions occurring on plaques of morphea.</p>
        <list list-type="bullet">
          <list-item>
            <p>Linear scleroderma manifests as thickened and indurated skin bands, which are most often on the face or extremities. It is the most common form of scleroderma in children.&#x000a0;</p>
          </list-item>
        </list>
        <p>On the scalp or face, linear scleroderma gives an aspect called "en coup de&#x000a0;sabre" (a French expression meaning &#x0201c;cut from a sword&#x0201d;). The sclerotic band&#x000a0;is generally&#x000a0;located&#x000a0;on the&#x000a0;forehead&#x000a0;but can extend to the scalp (causing scarring alopecia), and to the nose&#x000a0;as well as&#x000a0;the upper lip. The skin is hypo or hyperpigmented, atrophic and adheres to the underlying bone. This form of scleroderma can sometimes&#x000a0;be associated&#x000a0;with ipsilateral&#x000a0;hemiatrophy&#x000a0;of the face and is therefore hardly individualizable from Parry-Romberg syndrome.&#x000a0;</p>
        <p>Linear scleroderma of the limbs is called&#x000a0;"monomelic" and often begins in childhood. Sclero-atrophic bands appear gradually and then extend to the muscles and tendons; this may lead to an extreme aspect of pansclerotic morphea with joint and bone deformities sometimes associated with a stop or growth retardation of the limb.</p>
        <p>
<bold>Systemic scleroderma or systemic sclerosis</bold>
</p>
        <p>This form of scleroderma is the most severe since it usually affects several internal organs. However, most patients do not have all the symptoms described below.</p>
        <p>
<bold>Raynaud&#x02019;s phenomenon</bold>
</p>
        <p>Raynaud&#x02019;s phenomenon (RP) is secondary to distal arteries vasospasm after exposure to cold or temperature changes. It is the most common manifestation of systemic sclerosis, occurring in more than 95% of patients. The typical RP crisis includes three phases: syncopal pallor with anesthesia limited to a few fingers, cyanosis paresthesia, and late erythematous, painful phase. Trophic disorders, mainly digital ulcerations, often complicate RP. About 50% of systemic scleroderma patients will have during the course of the of their disease at least one episode of digital ulceration. Digital ischemia can eventually result in distal gangrene that may result in auto-amputation. In more than 95% of patients with SSc, nailfold capillaroscopy shows vascular anomalies, such as architectural disorganization, giant capillaries, hemorrhages, loss of capillaries, angiogenesis and avascular areas.<xref ref-type="bibr" rid="article-28781.r11">[11]</xref><xref ref-type="bibr" rid="article-28781.r12">[12]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Skin manifestations: </bold>
</p>
        <p>Skin lesions are bilateral and symmetrical, with a distal beginning, involving the fingers and sometimes the toes. Two clinical features should be distinguished&#x000a0;<xref ref-type="bibr" rid="article-28781.r12">[12]</xref><xref ref-type="bibr" rid="article-28781.r13">[13]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Diffuse SSc, during which cutaneous sclerosis rises above the elbows and knees, which represents 30 to 40% of all patients.</p>
          </list-item>
          <list-item>
            <p>Limited SSc, during which the cutaneous involvement limits itself to the fingers, hands, forearms, and face. Swelling of the fingers and hands may precede several months the onset of sclerotic lesions. Moreover, the skin of the fingers appears tense, giving a "sausage-like" appearance. The skin of the fingers becomes dry, thick and rough to the touch: this is called sclerodactyly, making it difficult to close the hand into a fist.</p>
          </list-item>
        </list>
        <p>The nails diminish in size, curl and sometimes disappear. The face takes an inexpressive appearance, with a waxy skin in which the folds fade. The nose and the lips thin. Due to skin xerosis, small wrinkles form on the skin around the lips, which become finer. The limitation of oral opening may constitute a limitation for the consumption of solid foods, dental care, and other actions. The ability to open the oral cavity is measured by the inter-incisor distance. Telangiectasias are common during SSc and are usually localized in the face and mucous membranes.</p>
        <p>Other cutaneous signs such as calcinosis, pigmentation disorders, and&#x000a0;telangiectasia may be present.</p>
        <p>Modified Rodnan skin score measures by palpation the extent and importance of cutaneous sclerosis in 17 zones of the body (0: normal cutaneous thickness; 1: minimal thickening; 2: moderate thickening; 3: thickening major). In diffuse forms, this score has a prognostic value, and usually reaches its maximum in the first three years after Raynaud's phenomenon and then tends to improve spontaneously.<xref ref-type="bibr" rid="article-28781.r14">[14]</xref></p>
        <p>
<bold>Pulmonary impairment</bold>
</p>
        <p>The pulmonary lesions include interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH). These two complications are the leading causes of death during SSc. &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Pulmonary arterial hypertension</bold>
</p>
          </list-item>
        </list>
        <p>Pulmonary arterial hypertension (PAH) occurs in up to 13% of patients with systemic scleroderma. It occurs more commonly in patients with limited cutaneous systemic sclerosis. By definition, PAH is pulmonary arterial pressure average greater than or equal to 25 mmHg measured at rest by right catheterization. PAH is suspected when pulmonary arterial systolic pressure exceeds 40 mm Hg at rest in echocardiography. Patients can remain asymptomatic for an extended time, especially if they do not have high levels of physical activity. Syncope, hemoptysis, and dysphonia (Ortner's syndrome) are signs of seriousness. An examination may find a systolic murmur of tricuspid insufficiency or diastolic murmur of pulmonary insufficiency, a loud second heart sound and signs of right heart failure.<xref ref-type="bibr" rid="article-28781.r15">[15]</xref> &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Interstitial lung disease (ILD)</bold>
</p>
          </list-item>
        </list>
        <p>Interstitial lung disease (ILD) is common in patients with SSc since up to 90% of patients exhibit evidence of interstitial changes on high resolution computed tomography (HRCT). It is more frequent with the diffuse forms of the disease. Pulmonary auscultation reveals crackles in the bases with or without a dry cough and dyspnea. ILD assessment is by pulmonary function tests (PFTs) and HRCT. The most classic finding is the ground-glass, and then appear linear or reticular images, septal or intralobular, then a honeycomb appearance with traction bronchiectasis. SSc-ILD appears in the early years of the disease, and its most marked progression occurs in the first years after diagnosis. ILD progression is usually slow; however, about 12% of scleroderma patients will progress to terminal respiratory failure. An ILD involving&#x000a0;more than&#x000a0;20% of the lung parenchyma correlates with poorer survival.<xref ref-type="bibr" rid="article-28781.r16">[16]</xref><xref ref-type="bibr" rid="article-28781.r17">[17]</xref><xref ref-type="bibr" rid="article-28781.r18">[18]</xref></p>
        <p>
<bold>Gastrointestinal</bold>
<bold> manifestations</bold>
</p>
        <p>Gastrointestinal involvement in SSc concerns the whole digestive tract. Gastroesophageal reflux disease (GERD) occurs in 75 to 90% of patients. If a patient complains from dysphagia, erosive esophagitis, peptic stenosis, and endo-brachy-esophagus should be ruled out. Motor impairment can also affect the stomach, causing gastroparesis and more rarely watermelon stomach, a condition related to gastric antral vascular ectasia. In the small bowel, the motor impairment leads to bacterial overgrowth, with concomitant nutritional deficiencies (folate and vitamin B12), malabsorption (steatorrhea), and pseudo-obstruction. Anorectal involvement may cause fecal incontinence and rectal prolapse.<xref ref-type="bibr" rid="article-28781.r19">[19]</xref></p>
        <p>
<bold>Cardiac manifestations </bold>
</p>
        <p>They are common in SSc. However, only 15% of patients are symptomatic and then have a poor prognosis (estimated 2-year mortality: 60%). Cardiac involvement includes myocardial disease, conduction system defects, arrhythmias, or pericardial disease.&#x000a0;&#x000a0;</p>
        <p>Usually, only the coronary microcirculation is affected. In the case of pulmonary disease, right heart failure is possible. Pericardial involvement is quite&#x000a0;common during SSc, usually without clinical consequence. Conduction disorders are quite&#x000a0;rare. Rhythm disorders are detectable by Holter-electrocardiography.<xref ref-type="bibr" rid="article-28781.r20">[20]</xref><xref ref-type="bibr" rid="article-28781.r21">[21]</xref></p>
        <p>
<bold>Renal involvement</bold>
</p>
        <p>Renal involvement is common in patients with SSc. The most serious manifestation is scleroderma renal crisis (SRC) which is a rare but major complication. It characteristically demonstrates the occurrence of sudden-onset hypertension and oligo/anuric acute renal failure. Clinical signs are those of malignant hypertension. SRC is more common in patients with diffuse SSc and having anti-RNA-polymerase III antibodies. Before the use of angiotensin-converting enzyme (ACE) inhibitors, SRC was the most common fatal complication of systemic scleroderma.<xref ref-type="bibr" rid="article-28781.r22">[22]</xref><xref ref-type="bibr" rid="article-28781.r23">[23]</xref></p>
        <p>
<bold>Musculoskeletal Manifestations</bold>
</p>
        <p>Scleroderma may affect joints (arthritis, arthralgia), tendons (rubs, tenosynovitis) and muscles (myalgia, weakness, more rarely myositis). Friction tendon rubs, seen on the hands, knees, and ankles, indicate a poor prognosis. Digital retractions in flexion due to skin sclerosis and calcinosis, lead to major functional disorders.<xref ref-type="bibr" rid="article-28781.r24">[24]</xref></p>
      </sec>
      <sec id="article-28781.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In patients with systemic scleroderma, the clinical assessment has two objectives: to confirm the diagnosis and to look for complications.</p>
        <p>Complementary exams to be performed if systemic scleroderma is suspected are: &#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Nailfold capillaroscopy</p>
          </list-item>
          <list-item>
            <p>Screening for antinuclear antibodies (mainly&#x000a0;anti-centromere&#x000a0;and anti-scl70/anti-topoisomerase antibodies)</p>
          </list-item>
          <list-item>
            <p>Transthoracic echocardiography&#x000a0;</p>
          </list-item>
          <list-item>
            <p>HRCT of the chest</p>
          </list-item>
          <list-item>
            <p>Diffusing capacity of the lung for carbon monoxide (DLCO) and spirometry</p>
          </list-item>
          <list-item>
            <p>Hand X-ray</p>
          </list-item>
          <list-item>
            <p>Esophageal manometry</p>
          </list-item>
        </list>
        <p>When the diagnosis of systemic scleroderma is established, in addition to previous exams, it is necessary to perform:</p>
        <list list-type="bullet">
          <list-item>
            <p>Electrocardiogram</p>
          </list-item>
          <list-item>
            <p>Complete blood count</p>
          </list-item>
          <list-item>
            <p>Renal and liver functions&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Urinalysis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>NT-pro-BNP dosage</p>
          </list-item>
          <list-item>
            <p>Upper gastrointestinal endoscopy</p>
          </list-item>
        </list>
        <p>Exams that should be done for follow-up each year are:</p>
        <list list-type="bullet">
          <list-item>
            <p>NT-pro-BNP dosage</p>
          </list-item>
          <list-item>
            <p>Spirometry and DLCO</p>
          </list-item>
          <list-item>
            <p>Transthoracic echocardiography</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28781.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Systemic Scleroderma</bold>
</p>
        <p>Treatment aims to relieve symptoms and to slow disease progression. No treatment can cure the disease. Therapeutic strategies should have their basis on a person&#x02019;s symptoms and the need to prevent complications. The use of different immunosuppressive drugs remains disappointing. Immunosuppressive therapy is reserved for diffuse SSc of recent diagnosis (less than 3 to 5 years) and patients with progressive PID. Its basis is on induction with cyclophosphamide then a relay by mycophenolate mofetil.</p>
        <p>The treatment of Raynaud's phenomenon is with calcium channel blockers. Protection against cold and smoking cessation are essential preventive measures. Patients should avoid drugs that worsen RP, in particular, beta-blockers (even as eye drops). In severe forms with trophic disorders, intravenous iloprost is a possible option. Bosentan has demonstrated efficacy in secondary prevention of digital ulcers.</p>
        <p>The treatment of esophageal involvement is with prokinetic agents and proton pump inhibitors. Treatment of diarrhea related to microbial overgrowth is with an antibiotic such as amoxicillin, norfloxacin or sulfonamides.</p>
        <p>ACE inhibitors have a significant place in the treatment of renal crisis but they are not recommended as prevention.</p>
        <p>As for other forms of PAH, scleroderma-associated PAH may be treated with drugs designed to relax the walls of the pulmonary arteries, or vasodilation. Oxygen therapy and anticoagulants may be useful. Diuretics can help reduce swelling.</p>
        <p>Corticosteroids may be useful in certain inflammatory manifestations of the disease as inflammatory joint manifestations and inflammatory myopathies.<xref ref-type="bibr" rid="article-28781.r11">[11]</xref><xref ref-type="bibr" rid="article-28781.r15">[15]</xref><xref ref-type="bibr" rid="article-28781.r16">[16]</xref><xref ref-type="bibr" rid="article-28781.r16">[16]</xref>&#x000a0; High doses of corticosteroids may induce scleroderma renal crisis.<xref ref-type="bibr" rid="article-28781.r17">[17]</xref><xref ref-type="bibr" rid="article-28781.r19">[19]</xref><xref ref-type="bibr" rid="article-28781.r22">[22]</xref></p>
        <p>
<bold>Localized scleroderma </bold>
</p>
        <p>Topical corticosteroids are the main treatment for plaque morphea. Generalized morphea may be treated&#x000a0;with combination therapy&#x000a0;of systemic steroids and methotrexate or with phototherapy. Linear scleroderma of the face or limbs&#x000a0;generally requires&#x000a0;the combination of systemic corticosteroids and methotrexate to avoid functional and/or esthetic disabilities.<xref ref-type="bibr" rid="article-28781.r1">[1]</xref></p>
      </sec>
      <sec id="article-28781.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Other conditions may cause changes of the skin clinically close to those observed during scleroderma. The differential diagnosis includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Scleredema (scleredema diabeticorum and scleredema of Buschke)&#x000a0;is&#x000a0;characterized by skin thickening, affecting the neck, upper back, shoulders, and trunk. Raynaud phenomenon and internal organ involvement are absent.<xref ref-type="bibr" rid="article-28781.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Eosinophilic fasciitis, often occurring following an unusual effort and characterized by edematous diffuse infiltration of the forearms and legs. It leads to the adherence of the skin to underlying fascia, usually sparing the hands and feet. Raynaud phenomenon is absent.</p>
          </list-item>
          <list-item>
            <p>Eosinophilia-myalgia syndrome, which is a form of&#x000a0;eosinophilia that is caused by&#x000a0;L-tryptophan.Graft-versus-host disease, an autoimmune pathology that occurs as a result of bone marrow transplants in which the immune cells from the transplanted bone marrow attack the host's body.</p>
          </list-item>
          <list-item>
            <p>Nephrogenic systemic fibrosis, which is usually caused by&#x000a0;kidney failure. Skin changes may be indistinguishable from scleroderma, but Raynaud phenomenon is typically absent. May have internal organ fibrosis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28781.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Life expectancy in patients with systemic sclerosis depends on the extent and severity of internal organ involvement. During SSc, the rate of death is 3.5 times higher compared to healthy subjects of the same age. The overall survival of patients with SSc is in the range of 75 to 80% after five years, 55% after ten years, 35 to 40% after 15 years and 25 to 30% after 20 years. &#x000a0;Factors correlating with a higher risk of death are advanced age at diagnosis, male patients, diffuse skin involvement, and visceral involvement (pulmonary, cardiac, renal). The pulmonary involvement is the main prognostic factor: five-year survival is greater than 90% in the absence of ILD and about 70% if ILD is present. The one-year survival is 55% in PAH associated with SSc. Autoantibodies also have a prognostic value: survival after ten years is 93% in the presence of anti-centromere antibodies, 66% in patients with anti-Scl70 and only 30% in patients with anti-RNA-polymerase III. The use of angiotensin-converting enzyme (ACE) inhibitors has transformed the prognosis of SRC, which remains an important cause of death.<xref ref-type="bibr" rid="article-28781.r7">[7]</xref><xref ref-type="bibr" rid="article-28781.r26">[26]</xref><xref ref-type="bibr" rid="article-28781.r27">[27]</xref><xref ref-type="bibr" rid="article-28781.r28">[28]</xref><xref ref-type="bibr" rid="article-28781.r29">[29]</xref></p>
        <p>In localized scleroderma, the hardening of the skin generally ceases&#x000a0;in the two years after the onset of the disease, and the lesions do not extend to other parts from the body. However, the disease can sometimes last several years, and some plaques may become more marked even after the end of&#x000a0;inflammation.&#x000a0;</p>
      </sec>
      <sec id="article-28781.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Skin hardening and musculoskeletal involvement in systemic scleroderma may cause functional disabilities, especially in hands. Oral opening limitations may alter food intake and dental care.</p>
        <p>Linear scleroderma of the limbs may cause functional disabilities, particularly if the disease affects the underlying bone. Linear scleroderma &#x0201c;en coup de sabre&#x0201d; may induce esthetic and/or functional concerns.</p>
      </sec>
      <sec id="article-28781.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated to stop smoking and avoid exposure to cold to prevent Raynaud's phenomenon. Using eye drops containing beta-blockers should also be avoided.</p>
      </sec>
      <sec id="article-28781.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional approach should include several medical specialties (dermatology, internal medicine, rheumatology, cardiology, pulmonology, gastroenterology, nephrology, radiology, biology) for the diagnosis and the treatment.</p>
        <p>Because of the musculoskeletal impairment frequently observed in scleroderma patients, kinesitherapy is often needed to prevent definitive damages.</p>
      </sec>
      <sec id="article-28781.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28781&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28781">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28781/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28781">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-28781.s14">
        <fig id="article-28781.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Bilateral Signs of Raynaud Phenomenon in a Patient's Hands. A male patient is exhibiting triphasic color changes in the digits of his hands, indicative of Raynaud Phenomenon. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="systemic__sclerosis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-28781.s15">
        <fig id="article-28781.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Pursed Mouth in a Female Patient With Scleroderma. This image shows a female patient with a pursed mouth, indicative of the cutaneous manifestations of scleroderma. Contributed by S Verma, MBBS, DVD, FRCP, FAAD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Pursed__mouth__of__scleroderma__SV1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-28781.s16">
        <title>References</title>
        <ref id="article-28781.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Careta</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Romiti</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Localized scleroderma: clinical spectrum and therapeutic update.</article-title>
            <source>An Bras Dermatol</source>
            <year>2015</year>
            <season>Jan-Feb</season>
            <volume>90</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <page-range>62-73</page-range>
            <pub-id pub-id-type="pmid">25672301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Denton</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Systemic sclerosis.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Oct</month>
            <day>07</day>
            <volume>390</volume>
            <issue>10103</issue>
            <fpage>1685</fpage>
            <page-range>1685-1699</page-range>
            <pub-id pub-id-type="pmid">28413064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Distler</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>J&#x000fc;ngel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Schulze-Horsel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Zwerina</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gay</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Michel</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schett</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Distler</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.</article-title>
            <source>Arthritis Rheum</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>311</fpage>
            <page-range>311-22</page-range>
            <pub-id pub-id-type="pmid">17195235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnett</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Reveille</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Mayes</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts.</article-title>
            <source>Arthritis Rheum</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>1359</fpage>
            <page-range>1359-62</page-range>
            <pub-id pub-id-type="pmid">11407695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Autoimmunity in systemic sclerosis: current concepts.</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2007</year>
            <month>May</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>165</fpage>
            <page-range>165-72</page-range>
            <pub-id pub-id-type="pmid">17502048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dumoitier</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lofek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mouthon</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of systemic sclerosis: state of the art in 2014.</article-title>
            <source>Presse Med</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>10 Pt 2</issue>
            <fpage>e267</fpage>
            <page-range>e267-78</page-range>
            <pub-id pub-id-type="pmid">25179277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayes</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lacey</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Beebe-Dimmer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Laing</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Schottenfeld</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.</article-title>
            <source>Arthritis Rheum</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>48</volume>
            <issue>8</issue>
            <fpage>2246</fpage>
            <page-range>2246-55</page-range>
            <pub-id pub-id-type="pmid">12905479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le Guern</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mouthon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jeanneret</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carzon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of systemic sclerosis in a French multi-ethnic county.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>9</issue>
            <fpage>1129</fpage>
            <page-range>1129-37</page-range>
            <pub-id pub-id-type="pmid">15213329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilbane</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2013</year>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <pub-id pub-id-type="pmid">23796020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venturi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pinna</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Pilloni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Atzori</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ferreli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rongioletti</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Bullous morphoea: a retrospective study.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>532</fpage>
            <page-range>532-535</page-range>
            <pub-id pub-id-type="pmid">28543394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hachulla</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Clerson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Launay</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morell-Dubois</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Queyrel</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hatron</surname>
                <given-names>PY</given-names>
              </name>
            </person-group>
            <article-title>Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study.</article-title>
            <source>J Rheumatol</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>12</issue>
            <fpage>2423</fpage>
            <page-range>2423-30</page-range>
            <pub-id pub-id-type="pmid">17985402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cutolo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sulli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Secchi</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Paolino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pizzorni</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement?</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>45 Suppl 4</volume>
            <fpage>iv43</fpage>
            <page-range>iv43-6</page-range>
            <pub-id pub-id-type="pmid">16980724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LeRoy</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Medsger</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Criteria for the classification of early systemic sclerosis.</article-title>
            <source>J Rheumatol</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>7</issue>
            <fpage>1573</fpage>
            <page-range>1573-6</page-range>
            <pub-id pub-id-type="pmid">11469464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Allanore</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Czirjak</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Distler</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Foeldvari</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kuwana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matucci-Cerinic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mayes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Medsger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Seibold</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Steen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.</article-title>
            <source>J Scleroderma Relat Disord</source>
            <year>2017</year>
            <season>Jan-Apr</season>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-18</page-range>
            <pub-id pub-id-type="pmid">28516167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Legendre</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mouthon</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Pulmonary arterial hypertension associated with connective tissue diseases].</article-title>
            <source>Presse Med</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>9</issue>
            <fpage>957</fpage>
            <page-range>957-69</page-range>
            <pub-id pub-id-type="pmid">25129118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schoenfeld</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Castelino</surname>
                <given-names>FV</given-names>
              </name>
            </person-group>
            <article-title>Interstitial lung disease in scleroderma.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2015</year>
            <month>May</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>237</fpage>
            <page-range>237-48</page-range>
            <pub-id pub-id-type="pmid">25836640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hinchcliff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Varga</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Systemic sclerosis/scleroderma: a treatable multisystem disease.</article-title>
            <source>Am Fam Physician</source>
            <year>2008</year>
            <month>Oct</month>
            <day>15</day>
            <volume>78</volume>
            <issue>8</issue>
            <fpage>961</fpage>
            <page-range>961-8</page-range>
            <pub-id pub-id-type="pmid">18953973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goh</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Veeraraghavan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hansell</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Copley</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Corte</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Sander</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Ratoff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Devaraj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bozovic</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>du Bois</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>AU</given-names>
              </name>
            </person-group>
            <article-title>Interstitial lung disease in systemic sclerosis: a simple staging system.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2008</year>
            <month>Jun</month>
            <day>01</day>
            <volume>177</volume>
            <issue>11</issue>
            <fpage>1248</fpage>
            <page-range>1248-54</page-range>
            <pub-id pub-id-type="pmid">18369202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirby</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and management of gastrointestinal manifestations in scleroderma.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>621</fpage>
            <page-range>621-9</page-range>
            <pub-id pub-id-type="pmid">25207461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steen</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Medsger</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Severe organ involvement in systemic sclerosis with diffuse scleroderma.</article-title>
            <source>Arthritis Rheum</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>43</volume>
            <issue>11</issue>
            <fpage>2437</fpage>
            <page-range>2437-44</page-range>
            <pub-id pub-id-type="pmid">11083266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clements</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lachenbruch</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Paulus</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Sterz</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Cardiac score. A semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis.</article-title>
            <source>Arthritis Rheum</source>
            <year>1991</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>11</issue>
            <fpage>1371</fpage>
            <page-range>1371-80</page-range>
            <pub-id pub-id-type="pmid">1835389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steen</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>Kidney involvement in systemic sclerosis.</article-title>
            <source>Presse Med</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>10 Pt 2</issue>
            <fpage>e305</fpage>
            <page-range>e305-14</page-range>
            <pub-id pub-id-type="pmid">25174767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mouthon</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Systemic sclerosis: views and thoughts for the future.</article-title>
            <source>Presse Med</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>10 Pt 2</issue>
            <fpage>e265</fpage>
            <page-range>e265-6</page-range>
            <pub-id pub-id-type="pmid">25220439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;r&#x000e1;nd</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Czirj&#x000e1;k</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Minier</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Musculoskeletal involvement in systemic sclerosis.</article-title>
            <source>Presse Med</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>10 Pt 2</issue>
            <fpage>e315</fpage>
            <page-range>e315-28</page-range>
            <pub-id pub-id-type="pmid">25179276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Debbiche</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koubaa</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mokhtar</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fenniche</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[A cutaneous infiltration: scleredema diabeticorum].</article-title>
            <source>Presse Med</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>40</volume>
            <issue>10</issue>
            <fpage>982</fpage>
            <page-range>982-4</page-range>
            <pub-id pub-id-type="pmid">21398082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lofgren</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hinchcliff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carns</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aren</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Arroyo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valenzuela</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haemel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wolters</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spiera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Assassi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fiorentino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Utz</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Whitfield</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Khatri</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity.</article-title>
            <source>JCI Insight</source>
            <year>2016</year>
            <month>Dec</month>
            <day>22</day>
            <volume>1</volume>
            <issue>21</issue>
            <fpage>e89073</fpage>
            <pub-id pub-id-type="pmid">28018971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koh</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gladman</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Abu-Shakra</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients.</article-title>
            <source>Br J Rheumatol</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>35</volume>
            <issue>10</issue>
            <fpage>989</fpage>
            <page-range>989-93</page-range>
            <pub-id pub-id-type="pmid">8883438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawut</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Berekashvili</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Garofano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Goldsmith</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Widlitz</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Rosenzweig</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Kerstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barst</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>New predictors of outcome in idiopathic pulmonary arterial hypertension.</article-title>
            <source>Am J Cardiol</source>
            <year>2005</year>
            <month>Jan</month>
            <day>15</day>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-203</page-range>
            <pub-id pub-id-type="pmid">15642552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28781.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hudson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tatibouet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>D</given-names>
              </name>
              <collab>International Scleroderma Renal Crisis Study Investigators</collab>
            </person-group>
            <article-title>Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>666</fpage>
            <page-range>666-72</page-range>
            <pub-id pub-id-type="pmid">24176729</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
